Biomea Fusion doses first patient in OPAL obesity study
Biomea Fusion says the first patient has been dosed in its OPAL study evaluating icovamenib in combination with semaglutide in obesity.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.